Tivozanib (hydrochloride hydrate)

Tivozanib hydrochloride hydrate is the hydrate hydrochloride form of Tivozanib (HY-10977) . Tivozanib hydrochloride hydrate is a selective, orally active inhibitor for vascular endothelial growth factor receptor (VEGFR) -1, 2 3, with IC50s of 30, 6.5 and 15 nM, respectively. Tivozanib hydrochloride hydrate exhibits antitumor efficacy[1].

Product Specifications

CAS Number

[682745-41-1]

Product Name Alternative

AV-951 (hydrochloride hydrate) ; KRN951 (hydrochloride hydrate)

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

VEGFR

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/tivozanib-hydrochloride-hydrate.html

Purity

99.83

Solubility

DMSO : 125 mg/mL (ultrasonic) |DMSO : 250 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(NC1=CC=C(C=C1Cl)OC2=CC=NC3=CC(OC)=C(C=C23)OC)NC4=NOC(C)=C4.Cl.O

Molecular Formula

C22H22Cl2N4O6

Molecular Weight

509.34

Precautions

H315, H319, H320

References & Citations

[1]Nakamura K, et al., KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res. 2006 Sep 15;66 (18) :9134-42.